Epitalon is a peptide derived from a small brain gland and promoted to slow aging by switching on the enzyme that rebuilds chromosome end-caps. Its strongest evidence sits at the cell and animal level; older-people data come from early Russian studies using the parent extract, never independently repeated. Short-term safety looks clean, but human longevity benefit remains unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Nighttime / morning melatonin (sleep-rhythm proxy) | Robust nocturnal rise; stable sleep timing | Tracks the circadian effect most plausibly linked to Epitalon |
| Telomere length (leukocyte) | Age-appropriate or higher percentile | Directly tests the signature telomerase claim |
| hs-CRP | < 1.0 mg/L | General inflammation/aging marker |
| Fasting glucose | 70–90 mg/dL | Metabolic aging marker reported to improve in elderly cohorts |
| HbA1c | < 5.4% | Longer-term glucose control |
| Lipid panel (LDL-C, HDL-C, triglycerides) | TG < 100 mg/dL; HDL-C > 50 mg/dL; LDL-C context-dependent | Lipid metabolism reported to normalize in treated elderly |
| CBC | Within normal limits | General health and infection screen given injection route |
| Age-appropriate cancer screening | No active malignancy | Addresses the theoretical telomerase-cancer concern before use |
Cadence: Baseline before the first course; before each course and roughly every 6–12 months for slower-moving markers, with sleep and qualitative markers tracked across each cycle.